Global private equity and venture capital news and research

Aerie’s venture backers eye strong stake valuations from imminent IPO $

22 Oct 2013

The venture capital-backers of eye disease treatment company Aerie Pharmaceuticals all plan to drop their stakes to below 20 per cent through the company’s impending IPO.

Sorry, you have reached your quota of 1 free article a week or you are attempting to read a Premium story.

To access the latest news and PREMIUM stories for FREE download the new AltAssets mobile app from the Google Play or App Store.

Legals & Terms of UsePrivacy Policy

AltAssets is registered as a trademark of Investor Networks Limited (06695690).
Registered Office: WeWork 4001, 1 Fore Street, London, EC2Y 5EJ
Content is © AltAssets 2000-2016